What Compugen (CGEN) Said on Its Q3 Earnings Call
Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.
How this was made

The 30-second read
Why it matters
Earnings beat and cash runway may prompt short‑term buying, while pending milestones could drive longer‑term upside.
Market read
Q3 earnings provide fresh financial data for CGEN, indicating improved loss profile and strong cash, which may influence short‑term price action.
What to watch
Milestone payments from AstraZeneca and Gilead could boost future cash flow beyond the disclosed numbers.
Background
Compugen (NASDAQ:CGEN) discussed its partnership milestones with AstraZeneca and Gilead and presented Q3 financial results.
Ticker impact
Q3 earnings disclosed revenue $3.8M, net loss $5.8M and cash $117.5M, new financial figures not previously public.
modest upside as market prices in improved loss profile and cash runway
First report of Q3 results shows better-than-expected loss narrowing and cash balance, likely to support short-term buying.
Market effects
Strengthens outlook for AI‑driven biotech discovery platforms.
Limited to US biotech micro‑cap segment.
Low global impact; primarily relevant to investors in CGEN.
Counterpoint
Losses remain sizable; investors may remain cautious despite narrowing.
Key entities
- companyCompugen Ltd.
Israeli clinical‑stage biotech focused on AI‑driven target discovery.
- partnerAstraZeneca
Pharma partner with potential $195M milestones.
- partnerGilead Sciences
Pharma partner with $90M payments and up to $758M milestones.


